Alpha-Gal Sensitization and Coronary Artery Disease What the Evidence Shows

Two large cohort studies have linked IgE sensitization to alpha-gal — the sugar antibody triggered by tick bites — with coronary artery disease and unstable plaque. A 2022 study of over 1,150 participants found that "the average soft plaque score was 300% higher than nonsensitized individuals (P <0.0001 for both)" (AHA 2022) — meaning the participants with alpha-gal antibodies had, on average, four times as much of the dangerous kind of artery plaque as people without those antibodies. Most people who develop these antibodies after a tick bite never experience the hallmark allergic reaction to red meat, yet the antibodies may matter for reasons that have nothing to do with dinner. For a primer on alpha-gal syndrome itself, see Alpha-Gal Syndrome: What It Is and How It Develops.

The research remains observational. No study has yet proven that alpha-gal IgE causes coronary artery disease. But the associations are large, consistent across cohorts, and independent of traditional risk factors — enough that researchers are now asking whether a tick bite could be a "novel, and potentially modifiable, risk factor for coronary atherosclerosis" (ATVB 2018). Atherosclerosis is the buildup of fatty plaque inside artery walls — the underlying process behind most heart attacks.

Is Alpha-Gal Syndrome Linked to Heart Disease?

Two major studies anchor the evidence. Both examined patients undergoing cardiac evaluation and tested their blood for IgE antibodies to alpha-gal. Neither was designed to prove causation, but their findings are striking in both size and specificity.

The 2018 Wilson Study

The first signal came from a study of patients undergoing cardiac catheterization — a procedure in which a thin tube is threaded into the heart's arteries to inspect them — in the southeastern United States. "IgE to α-Gal was detected in 26%, and atheroma burden was higher in sensitized subjects (P =0.02)." (ATVB 2018) In plain terms: about one in four patients had alpha-gal antibodies, and those patients had more atheroma — fatty deposits — building up in their arteries. The researchers used intravascular ultrasound, which images arteries from the inside, to look at the plaque — and found that the association was especially pronounced in younger patients:

"In subjects ≤65 years of age, the strength of the association with atheroma burden was stronger (P <0.001), and plaques in the sensitized group had less stable features based on intravascular ultrasound." — ATVB, 2018. IgE to the Mammalian Olig...

This was not a subtle trend. "the strength of the relationship with atheroma burden was stronger for α-Gal–specific IgE" (ATVB 2018) than for total IgE, and the association held "when adjusted for sex, diabetes mellitus, hypertension, statin use, and total IgE" (ATVB 2018) — meaning the link did not disappear when standard heart-disease risk factors were accounted for.

A critical detail: the relationship appeared specific to alpha-gal. "IgE to inhalants and peanut were assayed and were not associated with coronary artery disease." (ATVB 2018) People with hay fever or peanut allergy did not show the same pattern. The authors described their findings as "the first report that has described an association between the IgE response to α-Gal, or any specific allergen, and the burden of CAD" (ATVB 2018) (CAD being shorthand for coronary artery disease).

The 2022 Vernon Study

A larger study from Sydney, Australia, reinforced and extended those findings. Researchers tested over 1,000 patients undergoing coronary CT angiography — a CT scan that maps the heart's arteries — and a separate cohort of heart attack patients. The results were consistent across multiple measures of disease severity:

"α-Gal sensitization was associated with presence of noncalcified plaque (odds ratio, 1.62 [95% CI, 1.04–2.53], P=0.03) and obstructive CAD (odds ratio, 2.05 [95% CI, 1.29-3.25], P=0.002), independent of age, sex, and traditional risk factors." — AHA, 2022. Immunoglobulin E Sensitiz...

The difference in soft (noncalcified) plaque — the type most prone to rupture — was "1.3-fold higher incidence of soft plaque (68% versus 52%, P =0.002)" (AHA 2022). And "the incidence of obstructive CAD was 2.7-fold higher in the α-Gal sensitized patients compared with nonsensitized patients (49% versus 18%, P <0.001)" (AHA 2022) — meaning the alpha-gal group was nearly three times as likely to have arteries narrowed enough to restrict blood flow.

The heart attack cohort delivered some of the most dramatic numbers. "The α-Gal sensitization rate was 12.8-fold higher in patients with STEMI compared with matched healthy controls" (AHA 2022) — STEMI stands for ST-elevation myocardial infarction, the most severe type of heart attack — and "2.2-fold higher in the patients suffering STEMI compared with the matched stable CAD patients from the same geographic area (20% versus 9%; P =0.03)" (AHA 2022).

The association with noncalcified plaque and obstructive disease survived adjustment for traditional cardiovascular risk factors:

"α-Gal sensitization was significantly associated with obstructive CAD in both univariate and multivariable models (OR, 2.33 95% CI, 1.52–3.57, P <0.001; and OR, 2.05 95% CI, 1.29–3.25, P =0.002, respectively)." — AHA, 2022. Immunoglobulin E Sensitiz...

In their conclusions, the researchers stated that this "large study with over 1150 participants provides strong supportive evidence for a clinically important effect of α-Gal sensitization on the development of CAD and acute MI" (AHA 2022) — MI meaning myocardial infarction, the medical name for a heart attack.

Why Soft Plaque Matters

Both studies converge on the same pattern: alpha-gal sensitization is associated not just with more plaque, but with the dangerous kind. Noncalcified plaque — sometimes called "soft" or "vulnerable" plaque — is more likely to rupture and trigger a heart attack than its calcified, stable counterpart. Hardened, calcium-containing plaque tends to sit quietly; soft plaque is the type that can break open and form the clots behind most heart attacks. After adjusting for calcium scores, the Vernon study found the strength of the association actually grew stronger: "The OR conferred by α-Gal sensitization status for the presence of soft plaque increased from 1.62 (95% CI, 1.04–2.53; P =0.03) to 2.08 (95% CI, 1.21–4.60; P =0.008) after adjustment for CACS." (AHA 2022) OR is the odds ratio, a common statistical measure of how much more likely an outcome is in one group versus another; CACS is the coronary artery calcium score, which counts only the hardened plaque.

The earlier Wilson study had pointed in the same direction using a different imaging method, finding "an association between α-Gal sensitization and greater fibrofatty and necrotic plaque content" (AHA 2022) — that is, plaque made of soft fatty material and dead cell debris rather than stable calcium.

This specificity for unstable plaque helps explain why the association with acute heart attack was so pronounced — and why it may have been missed by studies looking only at calcified plaque, which standard calcium scoring detects.

Proposed Biological Mechanisms

Neither study could explain how alpha-gal IgE might drive plaque development. But several hypotheses have been proposed.

The Wilson team offered a central hypothesis: "chronic ingestion of α-Gal–glycosylated mammalian products, particularly the glycolipid form of the allergen, can lead to recurrent release of inflammatory products from mast cells bearing sIgE." (ATVB 2018) In other words, in people who carry these antibodies, eating mammalian meat — especially the fat-bound form of the alpha-gal sugar (a glycolipid) — could repeatedly nudge mast cells (immune cells that store inflammatory chemicals) to release small bursts of inflammation, even in people who never feel an obvious allergic reaction.

Research on how alpha-gal enters the bloodstream adds a piece to this picture. A 2019 study found that alpha-gal bound to lipids — rather than proteins — is absorbed through the gut and "could be also incorporated in the surface of chylomicrons, reaching the systemic circulation several hours after ingestion" (PMC 2019). Chylomicrons are tiny fat-carrying particles the gut releases into the blood after a fatty meal — meaning alpha-gal can hitch a ride on those particles and circulate through the body hours after eating. The same research group proposed that this lipid transport pathway "might not only explain the late beginning of the allergic reaction in α-Gal-allergic individuals, due to the slower process of digestion, absorption, and release to the lymphatics of lipids, but could also associate α-Gal with the worsening of certain cardiovascular diseases" (PMC 2019).

A 2021 review laid out an additional pathway involving macrophages — large immune cells that engulf debris and play a central role in plaque formation. The authors speculated that "the binding of these IgG1 antibodies to α-Gal molecules on the surface of chylomicrons could lead to the recruitment of macrophages and mediate the subsequent phagocytosis of the α-Gal-coated chylomicrons by macrophages, generating foam cells and thus, promoting the formation of atheromatous plaques" (FrontAllergy 2021). IgG1 is one class of antibody (distinct from IgE), and foam cells are macrophages so loaded with absorbed fat that they become part of the atheromatous plaque itself. The proposed sequence: alpha-gal-coated fat particles attract macrophages, the macrophages swallow them, become foam cells, and accumulate inside artery walls.

The Vernon study also highlighted that "the release of vasoactive inflammatory molecules, histamine, and leukotrienes, by activated mast cells is implicated in atherogenesis through increasing endothelial permeability, promoting the entry of circulating inflammatory cells and lipoproteins into the vessel wall" (AHA 2022). In simpler terms: when mast cells fire, they release chemicals — histamine and leukotrienes — that loosen the endothelium, the thin inner lining of blood vessels, allowing more inflammatory cells and fat-protein particles (lipoproteins) to seep into the artery wall, where plaque forms.

For a detailed look at how tick bites trigger alpha-gal sensitization in the first place, see How Tick Bites Trigger Alpha-Gal Sensitization.

The Hidden Population at Risk

The cardiovascular association appears strongest in people who have alpha-gal IgE but no allergic symptoms — which may be the majority of sensitized individuals. As the Wilson study noted, "many, or perhaps most, subjects with IgE to α-Gal do not have allergic symptoms" (ATVB 2018), meaning they "continue to consume foods that contain the oligosaccharide allergen" (ATVB 2018) — the oligosaccharide (a small chain of sugar molecules) being alpha-gal itself.

The Vernon study estimated that "<10% of α-Gal sensitized individuals in the study had experienced symptoms consistent with an α-Gal allergy" (AHA 2022). A separate review described alpha-gal sensitization as "a significant risk factor for coronary heart disease, even in people lacking clinical symptoms" (FrontCellInfectMicrobiol 2021).

This raises a difficult question about screening. The Vernon study noted that "the strong association with noncalcified plaque and the higher incidence of sensitization in STEMI patients provides modest evidence to support screening for IgE α-Gal in communities where ticks are endemic, or in individuals with high exposure risk through occupation or travel" (AHA 2022). A 2025 infectious diseases review echoed this cautiously: "if the recent evidence suggesting that asymptomatic patients with AG IgE may be at risk for CAD is confirmed in future studies, screening an asymptomatic patient presenting at least 4 weeks after a confirmed LST bite for AG IgE may be reasonable. However, it is not yet clear whether dietary modifications or tick bite avoidance would modify the CAD risk." (PMC 2025) (LST refers to the lone star tick, the species most associated with alpha-gal sensitization in the United States.)

The Specificity Question

A lingering concern with any IgE-cardiovascular link is whether the association is truly about alpha-gal or just reflects elevated total IgE — which has its own established relationship with atherosclerosis. The evidence so far suggests the link is specific.

The Wilson study found that "the association with CAD is stronger for α-Gal sIgE than total IgE" (ATVB 2018) — sIgE meaning specific IgE, the antibody pointed at one particular target — and that "sIgE antibodies to a panel of inhalants and peanut did not have a significant relationship with CAD" (ATVB 2018). The Vernon study's analysis built on this, concluding that "the relationship between total IgE and CAD may be predominantly driven by IgE α-Gal specific antibodies" (AHA 2022).

There is also a notable contrast between antibody types. Natural IgM and IgG antibodies to alpha-gal — which virtually all humans carry — appear to be protective. (IgM and IgG are different classes of antibody from IgE; IgE is the class involved in allergic reactions, while IgM and IgG handle other immune jobs.) As the Wilson study observed, "an inverse association between levels of α-Gal–specific IgM and IgG antibodies and CAD has been reported previously" (ATVB 2018). The problem seems specific to the class-switched IgE response triggered by tick bites — class-switching being the immune-system maneuver that converts a B cell from producing one antibody class (such as IgM) to another (such as IgE) — which "is in keeping with prior reports that natural antibodies to oxidation-specific epitopes are protective in atherosclerosis, whereas class-switched antibodies can be proatherogenic" (ATVB 2018). Proatherogenic simply means "tending to promote plaque buildup."

What Remains Unknown

Despite the strength of the association, causation has not been established. A 2020 review characterized the evidence plainly: "Circulating alpha-gal specific IgE has also been associated with an increased atherosclerotic burden and unstable plaques in the setting of coronary artery disease, although the association is not causal." (PMC 2020) A 2025 rapid review noted that the research base remains thin: "of those 34 studies, only 3 were in journals focusing on cardiology" (IJGM 2025), with the majority published in allergy and immunology journals.

The Vernon study called for "Prospective studies are required in tick endemic areas to better understand the association and potential causal role of α-Gal sensitization in the risk of MI" (AHA 2022). Whether avoiding tick bites can reduce cardiovascular risk remains an open question: "Avoidance of recurrent tick bites does reduce IgE α-Gal levels and over time many mammalian meat allergy sufferers are able to return to eating meat; however, whether this has any impact on the risk to CAD is unknown." (AHA 2022)

Alpha-gal sensitization also raises clinical considerations around medical devices and procedures that contain mammalian tissue. Those risks are explored in Alpha-Gal and Medical Procedures.

The implications for public health are potentially far-reaching. Alpha-gal sensitization rates vary by geography but track closely with tick populations: "α-Gal syndrome is relatively common in Southern Sweden where Ixodes ricinus is endemic, however, there are no reports of α-Gal sensitization in Northern Sweden where Ixodes ricinus is not found." (AHA 2022) (Ixodes ricinus is the castor bean tick, a common European tick species.) If the cardiovascular link holds, the Vernon study concluded, "Public policy and interventions that reduce exposure to tick bites should reduce α-Gal sensitization rates, with a potential beneficial impact on reducing CAD." (AHA 2022)

" These findings have substantial public health implications given the high rates of α-Gal sensitization in tick-endemic areas globally." — AHA, 2022. Immunoglobulin E Sensitiz...

Sources

    Not medical advice. See a healthcare provider for medical decisions. Medical Disclaimer